Home » Stocks » MRNS

Marinus Pharmaceuticals, Inc. (MRNS)

Stock Price: $12.73 USD 0.06 (0.47%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
Market Cap 451.01M
Revenue (ttm) 171,000
Net Income (ttm) -74.30M
Shares Out 30.55M
EPS (ttm) -3.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $12.73
Previous Close $12.67
Change ($) 0.06
Change (%) 0.47%
Day's Open 12.70
Day's Range 12.40 - 12.77
Day's Volume 236,552
52-Week Range 4.76 - 15.89

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 6 days ago

Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA...

Business Wire - 1 week ago

RADNOR, Pa.--(BUSINESS WIRE)-- #CDD--Marinus received a positive response from the FDA on sufficiency of Marigold Study data to support filing of NDA for the use of ganaxolone in CDD.

Business Wire - 2 weeks ago

RADNOR, Pa.--(BUSINESS WIRE)-- #HCWBioConnect--Marinus management will participate in the 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect 2021 Conference.

Zacks Investment Research - 2 weeks ago

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Other stocks mentioned: CBAY, EDIT, NTLA, VRTX
Business Wire - 4 weeks ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI).

The Motley Fool - 1 month ago

This can happen when a company holds out its hand for a big chunk of fresh capital.

Other stocks mentioned: ARCT, IBIO
Business Wire - 1 month ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals announces the pricing of an underwritten public offering of 5 million shares of its common stock for gross procee...

Business Wire - 1 month ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals announces an underwritten public offering of its common stock.

Business Wire - 1 month ago

RADNOR, Pa.--(BUSINESS WIRE)-- #AES2020--Marinus Pharmaceuticals will provide additional ganaxolone data during #AES2020 Scientific Exhibit.

Business Wire - 1 month ago

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals announced the grant of inducement awards to two new employees.

Business Wire - 1 month ago

RADNOR, Pa.--(BUSINESS WIRE)-- #AES2020--Marinus Pharmaceuticals will host a webinar with updates on its programs in status epilepticus, CDD, and TSC at #AES2020.

Business Wire - 1 month ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #AES2020--Marinus Pharma. to present updates and data from its trials in CDKL5 and refractory status epileptics at American Epilepsy Society's conference.

Business Wire - 2 months ago

RADNOR, Pa.--(BUSINESS WIRE)-- #MarinusPharma--Marinus Pharmaceuticals announced the grant of inducement awards to two new employees.

Seeking Alpha - 2 months ago

Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 17.74% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead...

Business Wire - 2 months ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #CDKL5--Marinus Pharmaceuticals provides a business update following its "milestone" third quarter.

Business Wire - 2 months ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #ChiefCommercialOfficer--Marinus Pharmaceuticals appoints Christy Shafer as Chief Commercial Officer. Shafer will report to CEO Dr. Scott Braunstein, and...

Business Wire - 3 months ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #FY2020--Marinus Pharmaceuticals will announce its financial results for the third quarter on November 9, 2020 following the close of market.

Business Wire - 3 months ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #GuggenheimHealthcareTakes--Marinus Pharmaceuticals announced that company management will participate in a number of investor healthcare conferences fro...

Business Wire - 3 months ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #BARDA--Marinus Pharmaceuticals has satisfied the FDA's protocol-specific questions for its Phase 3 trial in RSE and announces VPs, Clinical Development.

Business Wire - 3 months ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS--Marinus Pharmaceuticals announced that it will effect a one-for-four reverse stock split of its common stock at 5:00 pm ET today.

Zacks Investment Research - 3 months ago

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Other stocks mentioned: BBC, BTEC, IBBJ, IDNA, NVUS, PTH, SAVA, WVE
The Motley Fool - 4 months ago

Find out what's behind their big run-ups to see if they can make it happen again.

Other stocks mentioned: IMMU, VXRT
24/7 Wall Street - 4 months ago

The announcement of positive topline results in a late-stage epilepsy trial prompted a rally in Marinus Pharmaceuticals Inc.

The Motley Fool - 4 months ago

Investors are thrilled with the results from a late-stage clinical study of the company's only pipeline drug candidate.

Benzinga - 4 months ago

Shares of small-cap biopharma Marinus Pharmaceuticals Inc (NASDAQ: MRNS) were moving sharply higher to a new 52-week high Tuesday following the release of positive results for ganaxolone, the ...

Zacks Investment Research - 4 months ago

Marinus Pharmaceuticals (MRNS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Business Wire - 4 months ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #CDKL5--Marinus Pharmaceuticals' management will present at three investor conferences the week of September 14.

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.

Business Wire - 5 months ago

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #BizUpdate--Marinus Pharmaceuticals provides an update on its clinical development activities and reports financial results for the second quarter of 2020.

Benzinga - 5 months ago

Marinus Pharmaceuticals (NASDAQ: MRNS) shares are trading higher on Thursday after the company announced it has received FDA rare pediatric disease designation for Ganaxolone for the treatment...

Business Wire - 5 months ago

RADNOR, Pa.--(BUSINESS WIRE)-- #CDKL5--Marinus Pharmaceuticals, Inc.

Business Wire - 5 months ago

RADNOR, Pa.--(BUSINESS WIRE)-- #ClinicalTrial--Marinus Pharmaceuticals, Inc.

GlobeNewsWire - 6 months ago

RADNOR, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare ...

GlobeNewsWire - 6 months ago

RADNOR, Pa., June 24, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare ...

GlobeNewsWire - 6 months ago

RADNOR, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare ...

GlobeNewsWire - 7 months ago

RADNOR, Pa., June 15, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc.  (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orpha...

GlobeNewsWire - 7 months ago

RADNOR, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 18...

GlobeNewsWire - 7 months ago

RADNOR, Pa., May 28, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative t...

GlobeNewsWire - 7 months ago

RADNOR, Pa., May 28, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative t...

Seeking Alpha - 8 months ago

Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

Board includes 6 globally recognized seizure disorder experts Board includes 6 globally recognized seizure disorder experts

GlobeNewsWire - 8 months ago

RADNOR, Pa., April 27, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company” or “Marinus”), a pharmaceutical company dedicated to the development of innovative...

InvestorPlace - 8 months ago

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

Other stocks mentioned: ATRA, BHVN, CBAY, PTCT, SLDB, TBIO
GlobeNewsWire - 9 months ago

RADNOR, Pa., March 23, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company”, “Marinus”), a pharmaceutical company dedicated to the development of innovative t...

Zacks Investment Research - 10 months ago

Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.

GlobeNewsWire - 10 months ago

RADNOR, Pa., March 19, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orph...

GlobeNewsWire - 10 months ago

Top-line data on-track for Q3 2020 Top-line data on-track for Q3 2020

GlobeNewsWire - 11 months ago

RADNOR, Pa., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative ...

GlobeNewsWire - 1 year ago

Enrollment on-track for CDKL5 Deficiency Disorder Phase 3 readout Q3 2020

About MRNS

Marinus Pharmaceuticals, a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 31, 2014
CEO
Dr. Scott Braunstein
Employees
65
Stock Exchange
NASDAQ
Ticker Symbol
MRNS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for MRNS stock is "Strong Buy." The 12-month stock price forecast is 28.44, which is an increase of 123.41% from the latest price.

Price Target
$28.44
(123.41% upside)
Analyst Consensus: Strong Buy